GASTRIC/GASTRO-ESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA

Clinical trials for GASTRIC/GASTRO-ESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new GASTRIC/GASTRO-ESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for GASTRIC/GASTRO-ESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Could a lighter immunotherapy schedule keep advanced cancers in check?

Disease control Ongoing

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

Matched conditions: GASTRIC/GASTRO-ESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA

Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control

Last updated Jul 19, 2026 00:00 UTC

GASTRIC/GASTRO-ESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA

Get alerted when new GASTRIC/GASTRO-ESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA trials appear

Could a lighter immunotherapy schedule keep advanced cancers in check?